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Understanding Limitations in At-work Productivity in
Patients with Active Ankylosing Spondylitis: The Role
of Work-related Contextual Factors
Annelies Boonen, Caroline Boone, Adelin Albert, and Herman Mielants
ABSTRACT. Objective. To explore the effect of health-related and contextual factors on presenteeism, absen-
teeism, and overall work productivity loss in patients with active ankylosing spondylitis (AS).
Methods. Consecutive patients with AS starting their first tumor necrosis factor inhibitor and in paid
employment were eligible. Patients completed the Work Productivity and Activity Impairment
(WPAI) questionnaire for AS to assess presenteeism, absenteeism, and overall work productivity
loss in the previous 7 days. In addition, they answered questions about work characteristics (type,
characteristics of workplace, satisfaction of contacts with colleagues, and importance of work in
life) and health status [Bath AS Functional Index (BASFI), AS Disease Activity Score-C-reactive
protein (ASDAS-CRP)]. Physicians assessed the Bath Ankylosing Spondylitis Metrology Index,
presence of articular and extraarticular manifestations, comorbidities, and laboratory indicators of
inflammation. Stepwise regression models were computed to determine which work-related and
health-related factors contributed to WPAI outcomes.
Results. The study included 80 patients. The WPAI presenteeism, absenteeism, and overall work
productivity loss scores were 49.1%, 30.2%, and 53.1%, respectively. Presenteeism was associated
with higher BASFI, female sex, and poor quality of contact with colleagues. Absenteeism was
associated with increasing age, current smoking status, higher ASDAS-CRP, and low importance of
work for life. Overall work productivity loss was associated with female sex, higher BASFI, past
adaptation of job because of illness, number of working hours, and manual profession.
Conclusion. Both health-related and contextual factors contribute to work limitations in patients
with AS and suggest additional opportunities for improvement by addressing the working
environment. (First Release Nov 1 2014; J Rheumatol 2015;42:93–100; doi:10.3899/jrheum.131287)
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Ankylosing spondylitis (AS) is a chronic inflammatory
rheumatic disease that affects the axial skeleton, but can also
involve peripheral joints or tendons, as well as other organs
such as eye, bowel, and skin1. The symptoms related to
articular as well as extraarticular manifestations can lead to
impaired functioning and a reduction in the patient’s
health-related quality of life2. Because of the effects of AS,
patients may have problems in their ability to adjust to the
different demands of their job, which can lead to impair-
ments while at work (presenteeism), sick leave (absen-
teeism), and eventual withdrawal from the labor force3.
Patients with AS are more likely to be unemployed
compared with the general population4,5,6. 
In patients with paid work, insights into the effects of AS
on presenteeism, absenteeism, and overall work produc-
tivity are limited. The majority of studies addressing these
work outcomes have either described the magnitude of the
problem in unselected patients or assessed the effect of
tumor necrosis factor inhibitors (TNFi) on productivity in
intervention trials4,5,6,7,8,9,10,11,12,13,14. Fewer studies have
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explored the factors that contribute to presenteeism or sick
leave. In such studies, the effect of AS on the biomedical
aspects of the disease received attention, and these studies
suggested a clear association between limitations in physical
function and presenteeism, absenteeism, and work produc-
tivity7,12,15. However, in accordance with the International
Classification of Functioning, Disability, and Health model,
the role contextual factors play in work outcomes is increas-
ingly recognized16,17. Also, the Outcome MEasures in
Arthritis Clinical Trials explicitly highlights the relevance of
contextual factors in the recently proposed framework
selection of core outcomes and core measures18. A large
number of candidate contextual factors (either environ-
mental or personal) exist when addressing work outcomes19.
To date, there is no consensus on which contextual factors
have a relevant effect on these outcomes, independent of
health-related variables.
The objective of our study was to explore the effect of a
large number of work-related variables in addition to
health-related factors on presenteeism, absenteeism, and
overall work productivity loss in patients with AS eligible
for TNFi treatment.
MATERIALS AND METHODS
Study design. Ours is a prospective, multicenter, open-label, post-authori-
zation, observational study in Belgian patients with AS, focusing on the
effects of etanercept (ETN) on work productivity (clinicaltrials.gov
NCT01421303). The analyses of our present study are based on the
baseline data available at the end of the 1-year patient inclusion period.
Patients. To be eligible, patients were required to be ≥ 18 years old; have
active disease (as judged by their rheumatologist), and be eligible for ETN
treatment following the Belgian reimbursement criteria. They also had to
be employed, capable of understanding and willing to provide signed
informed consent, and capable of understanding and completing question-
naires. To meet the Belgian reimbursement eligibility criteria, patients were
required to meet the modified New York criteria for the diagnosis of AS,
have failed conventional therapy for AS, and to have all of the following: a
Bath AS Disease Activity Index (BASDAI) score of ≥ 420, a C-reactive
protein (CRP) value higher than the upper limit of normal, an inadequate
response to 2 or more nonsteroidal antiinflammatory drugs (NSAID) for at
least 3 months, absence of active or latent tuberculosis, and a prescription
for TNFi treatment from a board-certified rheumatologist. Exclusion
criteria included patients who had already initiated a procedure for work
disability/pension, previous use of TNFi either in commercial use or in a
study for the treatment of AS or a related spondyloarthropathy condition,
and history of or current psychiatric illness that would interfere with the
patient’s ability to comply with protocol requirements or give consent
(judged by the treating rheumatologist).
Assessments. The factors used in our study that contribute to presenteeism,
absenteeism, and overall work productivity loss follow the biopsychosocial
model proposed by the International Classification of Functioning,
Disability, and Health model (Figure 1). This model recognizes the impor-
tance of health-related and work-related or personal factors for at-work
productivity loss and sick leave.
Questionnaires. Patients completed the Work Productivity and Activity
Impairment (WPAI) questionnaire, which evaluated presenteeism, absen-
teeism, and overall work productivity loss21. The WPAI-AS asks for the
number of hours missed because of AS-related health in the last week
(Q2a), the number of hours missed for other reasons (Q2b), the number of
hours actually worked (Q3), and the effect of AS on productivity (0–10
scale, 10 = maximal effect on productivity) while at work (Q4). Impairment
while working because of problems (presenteeism) was calculated as Q4 ÷
10; work time missed because of problems (absenteeism) as Q2a ÷ (Q2a +
Q2b + Q3); and overall work productivity loss because of problems as:
[Q2a ÷ (Q2a + Q2b + Q3)] + [1 – (Q2a) ÷ (Q2a + Q2b + Q3)] × Q4 ÷ 10.
All quantities were multiplied by 100 to be expressed as percentages. The
question on activity impairment in nonpaid work was not considered in the
present analyses. To understand the absence over a longer period of time,
patients were also asked the number of working days they missed because
of AS in the past 3 months.
In addition to the WPAI-AS, patients reported on a number of personal
characteristics such as age, sex, educational level (finished primary or
lower professional school only/finished middle professional or secondary
school/finished higher professional school or university), and importance
of their work for their life (numerical rating scale 0–1, 10 = very
important). Patients also answered questions on a large number of job- and
work-related environmental factors. First, patients completed an open
question on their current profession, which was classified for further
analyses into manual jobs and nonmanual jobs. Second, patients were
asked whether, in the past, changes in their job were made because of their
disease (yes/no). In addition, they answered questions on job control and
autonomy (level at which I can plan work myself, work can be postponed,
work offers possibility for personal development; on a 4-point scale),
workplace characteristics (no. colleagues doing the same work, quality of
contact with colleagues; 0–10 scale, 10 very good), employer knows about
illness (no/yes and takes illness into account/yes, but does not take illness
into account), and job characteristics [irregular working hours and shift
work (yes/no), no. employees doing the same work (< 50, 50–200, > 200)].
All questions on job and job characteristics (except the questions on job
changes because of disease and  awareness of employer about illness) were
part of the Module Profession and Job of the PROductivity losses in
DISability Questionnaire (PRODISQ), a modular and validated question-
naire on work22.
Finally, biomedical aspects of disease were assessed through a series of
questionnaires or assessments. In addition to disease duration since
symptom onset and since diagnosis, the following disease activity and
functioning assessments had to be completed by patients or physicians:
physician global assessment (PGA), Bath AS Functional Index (BASFI)23,
BASDAI, Ankylosing Spondylitis Disease Activity Score [ASDAS; both
CRP and erythrocyte sedimentation rate (ESR) methods]24, Bath AS
Metrology Index (BASMI)25,26,27, and Bath AS Patient Global Score
(BAS-G)28. The treating physician indicated whether patients had currently
or ever experienced AS-related extraspinal disease or extraarticular
manifestations [anterior uveitis, cardiac involvement, lung involvement,
psoriasis, peripheral joint involvement (excluding hip and shoulder), hip or
shoulder involvement, inflammatory bowel disease (IBD), or other
gastrointestinal involvement], or ever had any AS-related surgery [total
knee, hip, shoulder, and elbow replacements (unilateral and bilateral),
wrist/hand/ankle/foot surgery, or spinal surgery].
Statistical analyses. Quantitative data were summarized as mean and SD,
or as median and interquartile range (IQR) for skewed distributions.
Normality was assessed by the Shapiro-Wilk test. Frequency tables were
used for categorical variables. Regression analysis was used to test the
effect of each individual health-related and contextual factor on presen-
teeism, absenteeism, and overall work productivity loss (as measured using
the WPAI-AS questionnaire). Then all factors related to any of the 3
specific outcomes of interest at the “p < 0.10 level” were processed into a
multivariate stepwise regression analysis for each outcome with both entry
and removal acceptance levels set at p = 0.05. Classical linear regression
analysis was used for presenteeism and overall work productivity loss,
which followed a normal distribution. In contrast, absenteeism displaying a
U-shape distribution was converted into a categorical variable (0%
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absence, 1–99%, and 100%) and analyzed by ordinal logistic regression.
Results were reported as regression coefficients with standard error. The
quality and strength of the regression was assessed by the multiple coeffi-
cient of determination R2 and by the area under the curve (AUC) for ordinal
logistic regression. Statistical significance was set at the 5% critical level
(p < 0.05). All calculations were done with SAS (version 9.3 for Windows,
SAS Institute) and S-PLUS (version 8.1, TIBCO Software Inc.) statistical
packages.
RESULTS
Demographics and disease characteristics. A total of 80
patients were screened and all were eligible for inclusion in
the study. Demographics and disease characteristics are
listed in Table 1. An equal proportion of male and female
patients were involved in the study. Median duration of
disease was 9.4 years since the first symptoms and 1.6 years
since diagnosis. The majority of patients (87.5%) were
currently receiving NSAID to treat their AS. Disease
activity was generally high with a mean BASDAI score
above the ≥ 4 cutoff that treatment guidelines use as a factor
to determine eligibility for TNFi treatment, and also
ASDAS-CRP/ESR levels pointed toward high disease
activity. Thirty patients (37.5%) had experienced either
extraspinal disease or extraarticular manifestations, and
15.1% presented comorbidities. Five patients (6.3%) had
undergone 1 or more AS-related surgical procedures: 
1 patient (1.3%) had a unilateral total hip replacement, 
1 (1.3%) had a unilateral total shoulder replacement, 
1 (1.3%) received wrist/hand/ankle/foot surgery, and 2
(2.5%) had undergone spinal surgery.
Job characteristics. Information about the patients’ work
life obtained from the work questionnaire is presented in
Table 2. Forty-two patients (53.2%) achieved a high
education level. The median working time since the first
paid job was 17 years, and only a minority of patients
(13.9%) changed jobs because of their illness. Twenty-one
patients (26.6%) made or received adaptations to their work
because of AS. The median number of hours worked was 38
per week, over 5 days per week. The majority of patients
(59.0%) had a manual profession. The largest proportions of
patients were considered employees (39.2%) or workers
(38.0%). Twenty-one patients (26.6%) indicated that they
could never organize their work themselves, 60.3% could
never postpone the execution of their work, and 16.9%
could never develop their skills in their job. Quality of
contact with colleagues was high (median 8.0, IQR 7–9). Of
the patients whose employers knew about their illness,
66.0% of them took it into account and 34.0% did not.
Patients considered work to be important for their life with
a median score of 8 (IQR 7–9).
Effect of AS on work productivity. The WPAI-AS presen-
teeism and absenteeism scores were 49.1% (SD 22.9) and
30.2% (SD 40.6), respectively, leading to a WPAI-AS
overall worker productivity loss of 53.1% (SD 25.7).
Absenteeism was reported as 0% by 38 patients, between 1
and 99% by 16 patients, and 100% by 13 patients. When the
recall period was extended to the past 3 months, 44.3% of
patients reported an absence from work with a median of 10
days (IQR 8–25). Considering the exact number of work
days per week reported by the patients, the median
percentage of missed work days over the past 3 months
amounted to 15.4% (IQR 9.9–38.5), which was lower than
the estimates based on the WPAI. When categorizing the
number of days absent because of AS in the last 3 months
95Boonen, et al: Work outcomes in AS
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Figure 1. Framework representing the biopsychosocial model of the International Classification of Functioning,
Disability and Health in which the target variable (participation, measured by the WPAI questionnaire) and the
exploratory variables that are used in the present analyses are indicated16. AS: ankylosing spondylitis; ASDAS:
Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index;
BASFI: Bath Ankylosing Spondylitis Functional Index; BASMI: Bath Ankylosing Spondylitis Metrology Index;
WPAI: Work Productivity Activity Index.
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Table 1. Demographics and disease characteristics. Quantitative data are
presented as mean (SD) or median (IQR).
Characteristic n = 80
Age, yrs 38.1 (9.1)
Male sex, n (%) 40 (50.0)
Disease duration, yrs
Symptoms 9.4 (4.6–15.5)
Diagnosis 1.6 (0.3–9.1)
Smoking status, n (%)
Current smoker 32 (40.5)
Ex-smoker 17 (21.5)
Non-smoker 30 (38.0)
Current medication, n (%)
Methotrexate 4 (5.0)
Sulfasalazine 10 (12.5)
Corticosteroids 3 (3.8)
NSAID 70 (87.5)
Comorbidities, n (%)
1 7 (8.8)
2 4 (5.0)
3 1 (1.3)
Systemic features, n (%)
Anterior uveitis 7 (8.8)
Psoriasis 9 (11.3)
Peripheral joint involvement 12 (15.0)
Hip involvement 8 (10.0)
Shoulder involvement 6 (7.5)
GI involvement: IBD 2 (2.5)
GI involvement: other 1 (1.3)
AS-related surgery, n (%)
Unilateral hip replacement 1 (1.3)
Unilateral total shoulder replacement 1 (1.3)
Wrist/hand/ankle/foot surgery 1 (1.3)
Spinal surgery 2 (2.5)
ESR, mm/h 15.5 (8–26)
CRP, mg/l 8.4 (3.5–19.3)
PGA 7 (5–8)
BASMI 2.8 (1.4)
BASFI 5.1 (2.0)
BASDAI 6.0 (1.7)
ASDAS-CRP 3.6 (0.8)
ASDAS-ESR 3.3 (0.8)
BAS-G 6.9 (1.5)
WPAI, %
Absenteeism 0 (0–57.9)*
Impairment, presenteeism 49.1 (22.9)
Work productivity loss 53.1 (25.7)
Activity impairment 70 (50–80)
Patients with sick leave, % 29 (43.3)
Length of sick leave in the 7 last days, hours 0 (0–30)
* Mean (SD) absenteeism (%): 30.2 (40.6). IQR: interquartile range;
NSAID: nonsteroidal antiinflammatory drug; GI: gastrointestinal; IBD:
inflammatory bowel disease; AS: ankylosing spondylitis; ESR: erythrocyte
sedimentation rate; CRP: C-reactive protein; PGA: physician global
assessment; BASMI: Bath Ankylosing Spondylitis Metrology Index;
BASFI: Bath Ankylosing Spondylitis Functional Index; BASDAI: Bath
Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing
Spondylitis Disease Activity Score; BAS-G: Bath Ankylosing Spondylitis
Global Score; WPAI: Work Productivity Activity Index.
Table 2. Profession and work situation. Quantitative data are presented as
mean (SD) or median (IQR).
Question n = 80
1) Time since first paid job*, yrs 17 (9–23)
2) Change job because of illness, yes (%) 11 (13.9)
3) Were there some adaptations of your job because 
of your illness? Yes, n (%) 21 (26.6)
4) Manual profession, yes (%) 46 (59.0)
5) How many hours per week are you working? 38 (35–40)
6) How many days per week are you working? 5 (5–6)
7) What is your highest diploma? n (%)
Primary school 1 (1.3)
Lower professional school 13 (16.5)
Secondary school 23 (29.1)
Higher education school 32 (40.5)
University degree 9 (11.4)
Postgraduate education 1 (1.3)
8) Can you organize your work yourself? Yes, n (%)
Never 21 (26.6)
Sometimes 28 (35.4)
Often 16 (20.3)
Always 14 (17.7)
9) Can you postpone the execution of your work? Yes, n (%)
Never 47 (60.3)
Sometimes 29 (37.2)
Often 2 (2.6)
Always 0 (0.0)
10) Is it possible for you to develop your skills in your job? Yes, n (%)
Never 13 (16.9)
Sometimes 30 (39.0)
Often 23 (29.9)
Always 11 (14.3)
11) Among your colleagues, how many are doing the 
same job (or comparable) as yours? 5 (2–12)
12) Give an estimation of the quality of the contacts with 
your colleagues in your actual position. 
(0 = very bad to 10 = very good) 8 (7–9)
13) Does your employer know about your illness? n (%)
No 25 (33.3)
Yes he/she does take it into account 33 (44.0)
Yes he/she does not take it into account 17 (22.7)
14) Are you working with an irregular schedule or with pauses? 
Yes, n (%) 26 (32.9)
15) Do you manage staff? Yes, n (%) 20 (25.3)
16) How many workers are there in your enterprise? Yes, n (%)
< 50 36 (45.6)
50–200 10 (12.7)
> 200 33 (41.8)
17) Which kind of work are you doing? Yes, n (%)
Worker 30 (38.0)
Employee 31 (39.2)
State employee 6 (7.6)
Independent 11 (13.9)
State employee + independent 1 (1.3)
18) Do you need to travel by car for your job (taking into 
account the travel home–work)? Yes, n (%) 49 (62.0)
19) During the last 3 months, did you have 1 or more absences at work?
Yes, n (%) 35 (44.3)
No. days 10 (8–25)
20) In terms of quality of life, what importance is given to your job? 
(0 = not very important to 10 = very important). 8 (7–9)
* For Question 1, patients were asked the year of their first job and this was
used to calculate the time since first paid job. IQR: interquartile range.
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(no absence, between 1 and 60 days absent, and the maximal
number of days absent), a moderate agreement was found
with the categorized absenteeism based on WPAI (Cohen κ
0.45, 95% CI 0.27–0.64)29.
Health-related and contextual factors associated with
presenteeism, absenteeism, and overall work productivity
loss. Univariate regression analyses revealed that 21
variables were associated at the p < 0.10 level with presen-
teeism, absenteeism, or overall work productivity loss: age,
sex, disease duration, number of comorbidities, current
smoker, past smoker, PGA, BASFI, BASDAI, ASDAS-CRP,
ASDAS-ESR, BASMI, BAS-G, adaptation of job to illness,
manual profession, number of hours worked/week,
education, quality of contacts with colleagues, employer
knows about illness and accounts for it, employer knows
about illness but does not account for it, and importance of
job for life. Only these covariates were included in the
stepwise regression analyses that led to the final models
reported in the following sections (Table 3). 
Presenteeism. Presenteeism was lower in men than in
women (p = 0.0027) and increased significantly (p <
0.0001) with BASFI. Presenteeism also decreased with the
quality of contact with colleagues (p = 0.0096).
Absenteeism. The final ordinal model (AUC = 0.80) showed
that assessed absenteeism increased with age (p = 0.033)
and ASDAS-CRP (p = 0.0062), and was higher among
current smokers (p = 0.0045). By contrast, it decreased with
the importance of job for life (p = 0.0047). When repeating
the analyses for work days absent in the past 3 months with
the same patients, stepwise regression showed that age (0.15
± 0.049, p = 0.023) and BAS-G (0.85 ± 0.30, p = 0.0052)
were the only significantly related factors (AUC = 0.82).
Overall work productivity loss. Overall work productivity
loss was lower in men (p = 0.0002) and higher in persons
who did manual work (p = 0.022), in those who adjusted
their job in the past because of their disease (p = 0.0009),
and in persons who worked more hours per week (p =
0.0045). Increasing limitations in physical function (BASFI)
were strongly associated with overall work productivity loss
(p < 0.0001). 
DISCUSSION
To the best of our knowledge, no study has investigated a
comprehensive set of work-related contextual factors and
their effect on absenteeism, presenteeism, and overall work
productivity loss in patients with active AS who have a paid
job. We have shown that, in addition to disease-related
factors such as BASFI or ASDAS-CRP, several contextual
factors composing “appraisal-based” variables, such as
quality of contact with colleagues and importance of work
for life as well as objective measures such as type of
profession and adaptations of job, were associated with
work productivity in patients with active AS.
The interest in presenteeism and absenteeism is
increasing because they are relevant outcomes by them-
selves and also because they can be indicators for future
work disability3,10. Patients in our study incurred substantial
loss in self-reported work productivity during the week
preceding the start of TNFi; presenteeism because of AS
was 49.1% and absenteeism because of AS was 30.2%,
resulting in an overall work productivity loss of 53.1%. This
was comparable with baseline data from the Adalimumab
Trial Evaluating Long-Term Efficacy and Safety in AS
(ATLAS) study in patients starting biological treatment12. In
the ATLAS trial (n = 205 working patients), scores of 41.7%
for presenteeism and 43.9% for overall work impairment
were similar to those reported here; however, a much lower
value of 9.0% for absenteeism was recorded. Other studies
among patients initiating biological treatment used different
scales to measure work outcomes, therefore hampering
direct comparisons7,8,30.
The association between disease-related factors and
presenteeism or absenteeism was also shown in several
other studies. In an unselected group of patients under the
care of rheumatologists (n = 72 working patients), age,
BASFI, and BASDAI were found to be associated with
presenteeism, but only BASFI was previously associated
with absenteeism15. A study evaluating 612 patients with AS
(n = 315 in employment) within UK rheumatology centers
found that BASDAI but also depression were associated
with absenteeism, and disease activity, depression, anxiety,
and self-efficacy played a role in presenteeism31. Among
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Table 3. Effect of health and contextual factors on presenteeism, absen-
teeism, and overall work productivity loss: final multivariate models after
stepwise variable selection.
Variable Coefficient (SE) p
Presenteeism, n = 50, R² = 0.56
Intercept 56.5 (13.7)
Male sex –14.6 (4.60) 0.0027
BASFI 6.87 (1.22) < 0.0001
Quality of contact –4.16 (1.54) 0.0096
Absenteeism, n = 65, AUC = 0.80*
Intercept 1 –4.18 (2.66)
Intercept 2 –2.55 (2.63)
Age 0.071 (0.033) 0.033
Current smoker 1.70 (0.60) 0.0045
ASDAS-CRP 1.11 (0.41) 0.0062
Importance of job in life –0.65 (0.23) 0.0047
Overall work productivity loss, n = 49, R² = 0.63
Intercept –73.6 (5.09)
Male sex –20.5 (5.09) 0.0002
BASFI 6.33 (1.35) < 0.0001
Adaptation of job due to illness, yes 18.7 (5.23) 0.0009
Profession, manual 12.0 (5.04) 0.022
No. hours worked per week, log 25.6 (8.56) 0.0045
* Ordinal logistic regression. BASFI: Bath Ankylosing Spondylitis
Functional Index; ASDAS-CRP: Ankylosing Spondylitis Disease Activity
Score–C-reactive protein.
 Rheumatology
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patients eligible for treatment with TNFi in a clinical trial
setting, a multivariate model in the ATLAS trial (n = 194
patients with paid work were analyzed) showed that
physical functioning (BASFI) was moderately and signifi-
cantly associated with presenteeism, and that BASDAI was
only weakly yet significantly associated with presen-
teeism12. In the Ankylosing Spondylitis Study for the
Evaluation of Recombinant Infliximab Therapy trial (n =
279 patients for the entire study cohort; 58% of them were
employed), BASFI was significantly associated with
productivity (at work, school, or home), using Spearman
correlation coefficients to examine factors7. In our study, the
different effects observed for the role of limitations in
physical function (BASFI was associated with presenteeism
and overall work productivity loss, but not absenteeism) and
disease activity (ASDAS was associated with absenteeism,
but not presenteeism or overall work productivity loss)
cannot be easily explained. Our data suggest that the level of
disease activity has a greater influence on the decision of
patients to stay at home, while the level of physical limita-
tions has a stronger independent influence of productivity
while at work. Interestingly, when exploring determinants of
days absent in the last 3 months, only age and BAS-G were
significant. It is not surprising that disease activity (or other
reported health outcomes) measured at the time of the
survey was unrelated to past sick leave that occurred up to 3
months before. BAS-G, on the other hand, includes the
global well-being because of AS in the past 6 months.
The role of contextual factors in relation to work
disability in AS has been reported in a number of previous
studies that revealed the nature of work (workload),
workplace support (such as contact with colleagues or
supervisors), work adaptations, and personal behavior
(coping) were associated with work disability6,31,32,33,
34,35,36,37,38,39,40
. However, the role of contextual factors in
relation to absenteeism was the focus of only 4
studies13,40,41,42, and no study has explored their effect on
presenteeism. Grazio, et al found the nature of the work to
be associated with sick leave41 and Guillemin, et al found
that the exposure to cold conditions and prolonged standing
postures showed a higher relative risk of longterm sick
leave42. Ward and Kuzis could not confirm a relationship
between physically demanding jobs with a decrease in work
hours or longterm sick leave40. When considering
disease-related variables and environmental factors
together, Boonen, et al showed in a 3-nation study (France,
Belgium, and the Netherlands) that manual jobs, indepen-
dent of BASFI, were associated with episodes of absen-
teeism13. In addition, the length of sick leave was higher for
those living in the Netherlands (which could be because of
the differences in the organization of the social security
system), patients with IBD, and BASDAI. It must be noted
that the majority of the existing studies were performed over
10 years ago and in older patients than in our study.
Interestingly, we demonstrated that “appraisal-based”
factors, such as importance of work for life and quality of
contact with colleagues, protected against adverse work
outcomes, while objective measures such as the number of
working hours and manual jobs increased the likelihood for
restrictions in labor force participation. Different contextual
factors were associated with the different work outcomes,
which could be due to the small number of patients (and
events when addressing absenteeism) influencing signifi-
cance levels, and therefore, the decision to include or
exclude some variables when computing the models.
Our present study has some other limitations that need to
be highlighted. Patients from only 1 country were observed
and this might influence the generalizability of the study.
For example, countries have different social security
systems and different work-related factors that might affect
work outcome. Also, the higher number of female patients
suggests some patients might have had nonradiographic
axial spondyloarthritis (nr-axSpA) rather than AS. Based on
the Belgian reimbursement criteria used for inclusion in our
study, patients with nr-axSpA should not have been
included; however, radiographs to verify this were not
available. We trusted the investigators’ diagnoses of active
AS. It must also be noted that the study patients were highly
selected in that they had high enough disease activity to
warrant TNFi therapy, but were still able to work. The
cross-sectional nature of the study did not allow for deter-
mining significant factors that also predict adverse work
outcome. Although we found that the effect of poor quality
of contact with work colleagues was related to presenteeism,
no information was collected on whether these colleagues
held a more senior position to the patients, were their peers,
or were junior staff. It is important to note that the
knowledge and concern about illness by employer played no
independent role with regard to work outcome. Lastly, while
we already assessed a large number of work-related factors,
generic measures of coping or self-efficacy were not
measured, and it remains unknown to what extent they
would have had an independent contribution.
Because not all potential contextual factors have been
explored in relation to work outcome and their independent
role is still conflicting, we think there is insufficient evi-
dence to make a firm recommendation to which contextual
factors should be included in work studies as an outcome.
Moreover, it seems that contextual factors that are important
for absence from work and presenteeism may be different
from predictors for withdrawal from work.
This analysis of patients in paid employment with active
AS found that BASFI, female sex, and quality of contact
with colleagues were significantly associated with presen-
teeism, and that the patient’s age contributed significantly to
absenteeism. Our data suggest that the interactions with
colleagues should receive more attention when assessing the
problems or restrictions in work productivity of patients
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with active AS. The followup at 6 and 12 months after ETN
treatment of the present cohort will provide longitudinal
data and further insights. 
REFERENCES
1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;
369:1379-90.
2. Kiltz U, van der Heijde D. Health-related quality of life in patients
with rheumatoid arthritis and in patients with ankylosing
spondylitis. Clin Exp Rheumatol 2009;27 Suppl 55:S108-11.
3. Bergström G, Bodin L, Hagberg J, Aronsson G, Josephson M.
Sickness presenteeism today, sickness absenteeism tomorrow? A
prospective study on sickness presenteeism and future sickness
absenteeism. J Occup Environ Med 2009;51:629-38.
4. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment
across chronic inflammatory rheumatic diseases and comparison
with the general population. J Rheumatol 2005;32:721-8.
5. Marengo MF, Schneeberger EE, Citera G, Cocco JA. Work status
among patients with ankylosing spondylitis in Argentina. J Clin
Rheumatol 2008;14:273-7.
6. Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R,
Schouten H, et al. Withdrawal from labour force due to work
disability in patients with ankylosing spondylitis. Ann Rheum Dis
2001;60:1033-9.
7. van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch
F, Williamson P, et al. Infliximab improves productivity and
reduces workday loss in patients with ankylosing spondylitis:
results from a randomized, placebo-controlled trial. Arthritis
Rheum 2006;55:569-74.
8. Haibel H, Song IH, Rudwaleit M, Listing J, Hildemann S, Sieper J.
Multicenter open-label study with infliximab in active ankylosing
spondylitis over 28 weeks in daily practice. Clin Exp Rheumatol
2008;26:247-52.
9. Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J. Influence of
biologic therapy on return to work in people with work disability
due to ankylosing spondylitis. Rheumatology 2008;47:481-3.
10. Kristensen LE, Petersson IF, Geborek P, Joud A, Saxne T,
Jacobsson LT, et al. Sick leave in patients with ankylosing
spondylitis before and after anti-TNF therapy: a population-based
cohort study. Rheumatology 2012;51:243-9.
11. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact
of anti-tumour necrosis factor alpha treatment on admissions to
hospital and days of sick leave in patients with ankylosing
spondylitis. Ann Rheum Dis 2004;63:1670-2.
12. Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der
Heijde D. Impact of age, sex, physical function, health-related
quality of life, and treatment with adalimumab on work status and
work productivity of patients with ankylosing spondylitis. 
J Rheumatol 2010;37:385-92.
13. Boonen A, van der Heijde D, Landewé R, Spoorenberg A, Schouten
H, Rutten-van Molken M, et al. Work status and productivity costs
due to ankylosing spondylitis: comparison of three European
countries. Ann Rheum Dis 2002;61:429-37.
14. Boonen A, de Vet H, van der Heijde D, van der Linden S. Work
status and its determinants among patients with ankylosing
spondylitis. A systematic literature review. J Rheumatol
2001;28:1056-62.
15. Boonen A, Brinkhuizen T, Landewe R, van der Heijde D, Severens
JL. Impact of ankylosing spondylitis on sick leave, presenteeism
and unpaid productivity, and estimation of the societal cost. Ann
Rheum Dis 2010;69:1123-8.
16. World Health Organization. International classification of functioning,
disability and health (ICF). [Internet. Accessed September 24, 2014.]
Available from: www.who.int/classifications/icf/en
17. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, et
al. Identification of the most common problems by patients with
ankylosing spondylitis using the international classification of
functioning, disability and health. J Rheumatol 2006;33:2475-83.
18. Boers M, Idzerda L, Kirwan JR, Beaton D, Escorpizo R, Boonen A,
et al. Toward a generalized framework of core measurement areas
in clinical trials: a position paper for OMERACT 11. J Rheumatol
2014;41:978-85.
19. Tang K, Escorpizo R, Beaton DE, Bombardier C, Lacaille D, Zhang
W, et al. Measuring the impact of arthritis on worker productivity:
perspectives, methodologic issues, and contextual factors. 
J Rheumatol 2011;38:1776-90.
20. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P,
Calin A. A new approach to defining disease status in ankylosing
spondylitis: the Bath Ankylosing Spondylitis Disease Activity
Index. J Rheumatol 1994;21:2286-91.
21. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D.
Validity, reliability and responsiveness of the Work Productivity
and Activity Impairment Questionnaire in ankylosing spondylitis.
Rheumatology 2010;49:812-9.
22. Koopmanschap MA. PRODISQ: a modular questionnaire on
productivity and disease for economic evaluation studies. Expert
Rev Pharmacoecon Outcomes Res 2005;5:23-8.
23. Calin A, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing
Spondylitis Functional Index. Br J Rheumatol 1995;34:793-4.
24. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F,
Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed
disease activity score in patients with ankylosing spondylitis. Ann
Rheum Dis 2009;68:1811-8.
25. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett
SL, Calin A. Defining spinal mobility in ankylosing spondylitis
(AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
26. van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear
definition of the Bath Ankylosing Spondylitis Metrology Index
(BASMI) and comparison with the 2-step and 10-step definitions.
Ann Rheum Dis 2008;67:489-93.
27. van der Heijde D, Deodhar A, Inman RD, Braun J, Hsu B, Mack
M. Comparison of three methods for calculating the Bath
Ankylosing Spondylitis Metrology Index in a randomized 
placebo-controlled study. Arthritis Care Res 2012;64:1919-22.
28. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing
Spondylitis Patient Global Score (BAS-G). Br J Rheumatol
1996;35:66-71.
29. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics 1977;33:159-74.
30. Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP,
Hyrich KL. Working status in patients with rheumatoid arthritis,
ankylosing spondylitis and psoriatic arthritis: results from the
British Society for Rheumatology Biologics Register.
Rheumatology 2010;49:1570-7.
31. Healey EL, Haywood KL, Jordan KP, Garratt A, Packham JC.
Impact of ankylosing spondylitis on work in patients across the
UK. Scand J Rheumatol 2011;40:34-40.
32. Ariza-Ariza R, Hernandez-Cruz B, Collantes E, Batlle E,
Fernandez-Sueiro JL, Gratacos J, et al. Work disability in patients
with ankylosing spondylitis. J Rheumatol 2009;36:2512-6.
33. Bakland G, Gran JT, Becker-Merok A, Nordvag BY, Nossent JC.
Work disability in patients with ankylosing spondylitis in Norway. 
J Rheumatol 2011;38:479-84.
34. Barlow JH, Wright CC, Williams B, Keat A. Work disability among
people with ankylosing spondylitis. Arthritis Rheum 2001;
45:424-9.
35. Cakar E, Taskaynatan MA, Dincer U, Kiralp MZ, Durmus O, Ozgul
A. Work disability in ankylosing spondylitis: differences among
working and work-disabled patients. Clin Rheumatol
99Boonen, et al: Work outcomes in AS
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
 Rheumatology
The Journal of on July 2, 2018 - Published by www.jrheum.orgDownloaded from 
2009;28:1309-14.
36. Chorus AM, Boonen A, Miedema HS, van der Linden S.
Employment perspectives of patients with ankylosing spondylitis.
Ann Rheum Dis 2002;61:693-9.
37. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a
study of 100 patients. Br J Rheumatol 1997;36:766-71.
38. Ramos-Remus C, Hernandez-Rios G, Duran-Barragan S, 
Sanchez-Ortiz A, Aceves-Avila FJ, Castillo-Ortiz JD, et al. 
Fifteen-year trends of long-term disability and sick leaves in
ankylosing spondylitis. Clin Rheumatol 2011;30:361-7.
39. Rkain H, Allali F, Bentalha A, Lazrak N, Abouqal R, 
Hajjaj-Hassouni N. Socioeconomic impact of ankylosing
spondylitis in Morocco. Clin Rheumatol 2007;26:2081-8.
40. Ward MM, Kuzis S. Risk factors for work disability in patients with
ankylosing spondylitis. J Rheumatol 2001;28:315-21.
41. Grazio S, Jajić Z, Nemcić T, Jajić I. [Work capacity evaluation in
patients with ankylosing spondylitis]. [Article in Croatian]
Reumatizam 1997;45:1-5.
42. Guillemin F, Briancon S, Pourel J, Gaucher A. Long-term disability
and prolonged sick leaves as outcome measurements in ankylosing
spondylitis. Possible predictive factors. Arthritis Rheum
1990;33:1001-6.
100 The Journal of Rheumatology 2015; 42:1; doi:10.3899/jrheum.131287
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
 Rheumatology
The Journal of on July 2, 2018 - Published by www.jrheum.orgDownloaded from 
